Ambrx welcomes Dr. Janet Loesberg to its Board of Directors

– USA, CA –  Ambrx Biopharma Inc., (NYSE: AMAM), a clinical-stage biopharmaceutical today announced the appointment of Dr. Janet Loesberg (Pharm. D.) to its Board of Directors.

“I am pleased to welcome Janet as the newest director to Ambrx’s Board. Janet brings with her more than three decades of experience in the pharmaceutical industry that spans the US, South America, Europe and Asia. I am confident that her perspective will prove valuable in driving Ambrx’s US and global strategy as we continue to progress our clinical development pipeline,” said Chairman and CEO, Dr. Feng Tian.

About Dr. Janet Loesberg

Dr. Janet Loesberg has over 30 years of pharmaceutical industry experience. Dr. Loesberg is currently SVPGlobal Medical Affairs at Blueprint Medicines, a leading precision therapy company, where she has been since March 2020. From September 2019 to March 2020, Dr. Loesberg was VP, Head of Portfolio and Project Management, Research & Development at Janssen, Pharmaceutical Companies of Johnson & Johnson where she was responsible for delivering the extensive pipeline on time and on budget. Dr. Loesberg also served in several executive roles at Bristol Myers Squibb from October 2007 to March 2019 including leading Medical Affairs for the launch of Opdivo in China, Brazil, Latin America, and many additional countries. She started her career at Pfizer, Inc. where she also held several US-based leadership roles.

Currently, Dr. Loesberg is a board member for All in Together, a non-profit organization that equips women with tools to drive meaningful policy change.

Dr. Loesberg holds a Pharm. D. degree from the University of Michigan, College of Pharmacy.

About Ambrx Biopharma Inc.

Ambrx is a clinical-stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next-generation antibody-drug conjugates, bispecific, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety, and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, Ambrx has clinical collaborations with multiple partners, for drug candidates generated using Ambrx technology.

For more information: https://ambrx.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.